Neola Medical Ab · OMXSTO:NEOLA
Neola Medical Ab — Q4 2025 Earnings Presentation
29 slides from Neola Medical Ab's earnings presentation, Feb 12, 2026
Slide 1: Q4 2025
Q4 2025 Published February 12, 2026 “This year we initiated our first clinical pilot study on preterm born babies in Sweden, representing the first real-world use of Neola® for continuous monitoring of its target patient population.” CEO Hanna Sjöström Neola Medical Q4, 2025
Slide 2: Neola Medical Presentation
Neola Medical Presentation, Hanna Sjöström David Folkesson CEO CFO Neola Medical since 2019 Neola Medical since 2024 2 Neola Medical Q4, 2025
Slide 3: Forward looking statements
Forward looking statements This presentation and our discussion include forward-looking statements regarding our business strategies, market opportunities, anticipated financial performance, product development, and other related topics. These statements involve inherent risks and uncertainties, inc
Slide 4: Neola Medical at a glance
2016 2020 Founded and based on Listed on Nasdaq First advanced technology North Growth Market with a Swedish heritage Stockholm 10 class 2 Employees in HQ in Medical device developed Lund, Sweden with for continuous lung office in USA monitoring 4 Neola Medical Q4, 2025
Slide 5: Designed to enable instant detection of pulmonary complications
Designed to enable instant detection of pulmonary complications for proactive care, reduced morbidity and improved quality of life Neola Medical Q4, 2025
Slide 6: Scalable business model and revenue streams
Scalable business model and revenue streams Neola® units Disposable probes Service agreements 6 Neola Medical Q4, 2025
Slide 7: Eight patent families covering all major assets
Eight patent families covering all major assets Medical Neola® device Disposables Patient groups & Secure product & Inhibit copy & future innovation competitiveness secure leverage Neola Medical Q4, 2025
Slide 8: Stanford Impact1 Company
Stanford Impact1 Company Neola® is selected as one of the most promising innovations in neonatal intensive care by Stanford University Access to FDA advisors, Led by Janene Fuerch, regulatory specialists Ass. Prof in Neonatology and commercialization at Stanford support in the U.S. Neola Medical Q4,
Slide 9: Current standard of care in need of new technology
Current standard of care in need of new technology Current monitoring methods are insufficient Monitoring method with Neola® - Snapshots of lung status - Continuous monitoring of lungs in real-time - Slow - Instant - Invasive - Non-invasive - Non-radiation Pulse oximetry Blood sampling X-ray EIT Ult
Slide 10: Early detection is key to avoid costly complications
Early detection is key to avoid costly complications 1.1 million <5 years 1st cause 50 % Preterm born babies die Most common cause of Respiratory failure Of very and extremely every year death of children <5 leading cause of death preterm born babies years of age after among preterm babies show sign
Slide 11: In neonatal care – every minute counts
In neonatal care – every minute counts Sources: WHO | Born too soon. WHO, http://www.who.int/maternal_ child_adolescent/documents/born_too_soon/en/ Joshi A, Kumar M, Rebekah G, Santhanam S. Etiology, clinical profile and outcome of neonatal pneumothorax in tertiary care center in South India: 13 yea
Slide 12: Clear drivers in a growing and non-cyclical market
Clear drivers in a growing and non-cyclical market Global neonatal respiratory device market USD million 2,165 2,051 1,947 1,853 1,767 1,688 1,616 1,550 ✓ Growing patient population ✓ High margins ✓ Global market 1 in 10 babies is born preterm every year – around 15 million babies worldwide 2025 202
Slide 13: Strong market potential with one Neola® per baby
Strong market potential with one Neola® per baby United Kingdom France 57,000 2,547 53,887 1,782 Preterm NICU care Preterm NICU care babies places babies places Germany United States 66,752 Preterm 2,140 NICU care babies places ▪ Focus market due to large number of newborns and the particularly high
Slide 14: 10 leading children's hospitals with NICUs
10 leading children’s hospitals with NICUs Target customers for market launch-800 beds Top 10 target pilot hospitals (# NICU beds) Pittsburgh (77) (40) Cincinnati (59) (35) Logo SF (50) Philadelphia (100) LA (91) Washington, DC (55) Columbus (130) Houston (173) 14 Neola Medical Q4, 2025 Source: Amer
Slide 15: U.S. study visits
U.S. study visits 15 Neola Medical Q4, 2025
Slide 16: Financial value for customers with Neola®
Financial value for customers with Neola® Include avoided costs and reduced length–of–stay Reduced length of stay in the NICU Reduced number of blood gas samples and chest x-rays Reduced manual observation time for nurses Potential reimbursement via MS-DRG payments Source: Based on Pricing project f
Slide 17: Focus 2025
Focus 2025 Continued market 1 Clinical studies 2 Regulatory process 3 preparations in the U.S Neola Medical Q4, 2025
Slide 18: Full year of 2025: clinical pilot study
Full year of 2025 Clinical pilot study in Sweden initiated following approval from Swedish authorities Evaluate the safety and performance of Neola® in preterm born babies 10 preterm born babies from 28 weeks gestational age and weight between 1000-3000 grams Study site at Södra Älvsborgs sjukhus (S
Slide 19: Clinical Pilot Study
Clinical Pilot Study Preliminary findings Robust safety profile of Neola® for this highly vulnerable patient group Variations in the data, providing valuable insights for further optimization of Neola® Key insights will be communicated once the study is completed and final results are available Neol
Slide 20: Full year of 2025: directed share issue
Full year of 2025 Directed share issue of approxametely 20 mkr Secured financing with institutional investors, alongside support from existing shareholders Strengthened shareholder base Enables focus on clinical validation Neola Medical Q4, 2025
Slide 21: Full year of 2025: first U.S. study site agreement
Full year of 2025 First U.S. Clinical Study Site Agreement Signed NICU at Children’s Regional Hospital at Cooper in Camden, New Jersey, USA Dr. Vineet Bhandari, serving as principal investigator Enables the initiation of U.S. clinical study on preterm born babies Neola Medical Q4, 2025
Slide 22: Full year of 2025: seven new patent grants
3 Full year of 2025 2 2 Seven new patent grants in key strategic markets Patent grants across Europe, China and the U.S. Protection of foundational and product-specific innovations IP portfolio one of our most strategically important assets Neola Medical Q4, 2025
Slide 23: Full year of 2025: strengthened leadership team
Full year of 2025 Strengthened leadership team Clinical Director – PhD in lung physiology and expertise in clinical strategy Director Disposable Product Development – expertise in disposable medical products for daily clinical use and full-scale mass production Neola Medical Q4, 2025
Slide 24: Financial information
Financial information 24 Neola Medical Q4, 2025
Slide 25: Financials
Financials Fourth quarter, October-December 2025 Yearly report, January-December 2025 Summary Summary Operating income: SEK 0k (0) Operating income: SEK 0k (0) Operating result: SEK -2 520 (-2 742) Operating result: SEK -8 573k (-10 797) The period’s cash flow: SEK -6 000k (-4 606) The period’s cash
Slide 26: About the share
About the share Share capital, shareholders and the share 2025-12-31 As of December 31st, 2025, Neola Medical’s share capital was 5 567 896,30 SEK Amount of Percentage Percentage of with a total of 77 950 234 shares. All shares are of the same type, have an equal Shareholders 2025-12-31 (Top 10) sha
Slide 27: Financial calendar and contact
Financial calendar and contact 21 19 28 20 18 Apr 2026 May 2026 May 2026 Aug 2026 Nov 2026 Annual report 2026 Q1 report 2026 Annual General Assembly Q2 report 2026 Q3 report 2026 in Lund Financial reports Questions about the report is answered by: Financial reports are available at www.neolamedical.
Slide 28: Investment highlights
Investment highlights 1 Unmet clinical need and demand 2 Patented innovative technology 3 Growing addressable market 4 Scalable business model 5 Proven team and network Neola Medical Q4, 2025
Slide 29: LinkedIn I Facebook I Website
LinkedIn I Facebook I Website Neola Medical Q4, 2025